Immunate

Human Coagulation Factor VIII and Human Von Willebrand Factor, the active ingredient in Immunate, is a coagulation factor replacement presented as a sterile solution for intravenous use. It replaces deficient factor VIII and von Willebrand factor, restoring normal clotting in patients with hemophilia A and von Willebrand disease.

GNH USA supplies Immunate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Immunate is used to treat bleeding disorders that involve deficiencies in clotting factors.

Hemophilia A: Restores factor VIII activity to reduce bleeding frequency and severity. Von Willebrand disease: Provides von Willebrand factor to improve platelet adhesion and stabilize factor VIII, controlling mucosal and surgical bleeding.

Immunate may cause a range of adverse reactions following intravenous infusion.

Common Side Effects: - Infusion site erythema or pain - Headache - Low-grade fever - Nausea - Arthralgia - Mild skin rash

Serious or Rare Side Effects: - Anaphylactic reaction - Development of inhibitory antibodies against factor VIII or VWF - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe allergic response (angioedema, urticaria)

Prior to administration, clinicians should evaluate patient history and monitor for potential complications.

Monitor inhibitor development: Test for anti‑factor VIII antibodies periodically. Assess bleeding history: Adjust dose based on severity and frequency of bleeds. Avoid concurrent high‑dose procoagulants unless clinically indicated. Use caution in patients with cardiovascular disease or a history of thrombosis. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concomitant use with other clotting factor concentrates may increase risk of thrombosis. - Simultaneous administration with activated prothrombin complex concentrates can potentiate clot formation.

Moderate Interactions (Monitor Closely): - Use with antifibrinolytic agents (e.g., tranexamic acid) may enhance clot stability; monitor for excessive clotting. - Concurrent immunosuppressive therapy may influence inhibitor formation; observe antibody titres. - Administration with heparin may alter coagulation test results; adjust monitoring accordingly.